Objective Capital’s Dr. David Crean to Address International Bar Association’s 5th Annual World Life Sciences Conference in San Diego, CA

Objective Capital’s Dr. David Crean to Address International Bar Association’s 5th Annual World Life Sciences Conference in San Diego, CA

Panel Discussion on Life Sciences Transactions, Research Collaborations, and Licensing Models to be presented on June 17, 2017

San Diego, CA- May 31, 2017 – Objective Capital Partners, a leading M&A investment banking firm specializing in middle market M&A and capital raise, healthcare & life sciences and valuation advisory services, is pleased to announce that one of its Managing Directors, David H. Crean, Ph.D., will serve as a panel member and address legal professionals at the 5th Annual World Life Sciences Conference, June 16–17, 2017 at the Westin San Diego Gaslamp Quarter, San Diego, CA. The conference is presented by the International Bar Association (IBA), a global voice for the legal profession. The event will feature dynamic roundtable sessions covering the hottest topics and the latest developments from across the different sectors of the Life Science Industry.
Dr. Crean leads Objective Capital’s growing life sciences and healthcare practice.  He will serve as a panelist alongside fellow experts including Marco Blei (Portolano Cavallo, Milano, Italy), David Gilmann (Huron Consulting Group, New York, N.Y.), Rosemarie Tully (Chief Business Officer, Sigmoid Pharma Limited, Dublin, Ireland), Gabriel L. Kleiman (Pfizer, New York, N.Y.) and Amir Naiberg (Associate Vice Chancellor; CEO & President, UCLA Technology Development Corporation, Los Angeles, CA).  The panel will be moderated by Yuval Horn (Horn & Co, Tel Aviv, Israel) and Dr. Matthias Nordmann (SKW Schwarz, Munich, Germany).

For more information about the IBA event and to register, please visit http://www.ibanet.org/CONFERENCES/CONF797.ASPX.

About IBA

The International Bar Association, established in 1947, is the world’s leading organization of international legal practitioners, bar associations and law societies. The IBA influences the development of international law reform and shapes the future of the legal profession throughout the world. It has a membership of more than 80,000 individual lawyers and more than 190 bar associations and law societies spanning over 160 countries. It has considerable expertise in providing assistance to the global legal community. For more information, visit http://www.ibanet.org/.

About Objective Capital Partners

Objective Capital Partners is a leading M&A investment banking firm whose Principals have collectively engaged in more than 500 successful transactions serving the transaction needs of growth stage and mid-size companies. The executive team has a unique combination of investment banking, private equity, and business ownership experience that enables Objective Capital Partners to provide large enterprise caliber investment banking services to companies.  The firm focuses on middle market M&A and capital raise activities for companies with enterprise values between $10-100 million, healthcare & life sciences and valuation advisory services. The firm’s industry expertise includes software and hardware technology, life sciences, business services, IT services, healthcare services, biotech, consumer products and specialized manufacturing. Securities and investment banking services are offered through BA Securities, LLC Member FINRA, SIPC. Dr. Crean and other Principals of Objective Capital are Registered Representatives of BA Securities. Objective Capital Partners and BA Securities are separate and unaffiliated entities. Additional information on Objective Capital Partners is available at www.objectivecp.com.


This news release is for informational purposes only and does not constitute an offer, invitation or recommendation to buy, sell, subscribe for or issue any securities. While the information provided herein is believed to be accurate and reliable, Objective Capital Partners and BA Securities, LLC make no representations or warranties, expressed or implied, as to the accuracy or completeness of such information. All information contained herein is preliminary, limited and subject to completion, correction or amendment. It should not be construed as investment, legal, or tax advice and may not be reproduced or distributed to any person.

# # #



Mandy F. Woods

Business Office Manager

Objective Capital Partners

Tel: 858-208-3442


The Math Behind the Aftermath Driving a Private-Public Merger Transaction: Mast Therapeutics and Savara


I would like more information about...

Connect With Us